Gland Pharma (BOM:543245) Beta: 0.2717 (As of Jul. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:543245 Gland Pharma Ltd BOM:543245
84 GF Score
Price ₹2,440.25
GF Value ₹2,147.94
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Gland Pharma Beta?

Gland Pharma BOM:543245 -1.78% 84 Beta is 0.2717 as of Jul. 23, 2026. GuruFocus rates BOM:543245 with a GF Score™ of 84/100 and a GF Value™ of ₹2,147.94 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-23), Gland Pharma's Beta is 0.2717.


Gland Pharma  (BOM:543245) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Gland Pharma Beta Related Terms


Gland Pharma Beta Historical Data

* Premium members only.

The historical data trend for Gland Pharma's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gland Pharma Beta Chart

Gland Pharma Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beta
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.43 0.44 0.40

Gland Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.44 0.34 0.46 0.52 0.40

BOM:543245 vs ZTS, UTHR: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Gland Pharma's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gland Pharma Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's Beta distribution charts can be found below:

* The bar in red indicates where Gland Pharma's Beta falls into.


BOM:543245
84GF Score
Gland Pharma Ltd BOM:543245
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gland Pharma Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.2717 mean?
Gland Pharma (BOM:543245) has a Beta of 0.2717 as of Jul. 23, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Gland Pharma and its competitors.
Is Gland Pharma's Beta too high?
Gland Pharma's current Beta is 0.2717. Overall, Gland Pharma has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's Beta compare to ZTS and UTHR?
Gland Pharma's Beta of 0.2717 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Gland Pharma and its competitors. Gland Pharma's current Beta is 0.2717. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (BOM:543245) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,147.94, compared to a current price of ₹2,440.25 — trading 13.6% above its estimated fair value. The current Beta is 0.2717. Gland Pharma's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Gland Pharma (BOM:543245), the current Beta is 0.2717 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gland Pharma (BOM:543245) Overvalued in 2026?

Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued. The current stock price of ₹2,440.25 is trading 13.6% above its estimated GF Value™ of ₹2,147.94. GuruFocus considers Gland Pharma to be Modestly Overvalued.

Key valuation signals for BOM:543245:

  • Beta: 0.2717
  • GF Value™: ₹2,147.94 vs. price of ₹2,440.25 (13.6% above fair value)
  • GF Score™: 84/100 with 7 warning signs

No single metric tells the full story. See the BOM:543245 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gland Pharma Business Description

Other Exchanges GLAND:India
Address TSIIC, Phase - IV, Plot No. 11 and 84, Pashamylaram (V), Patancheru M, Sangareddy District, Hyderabad, TG, IND, 502307
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
84GF Score

Get the complete analysis for BOM:543245

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,440.25
Price
₹2,147.94
GF Value